OBR Daily Commentary

forumImage

UCSF, UCLA Gain FDA Approval for Prostate Cancer Imaging Technique

(UCSF) Dec 1, 2020 - The University of California’s two nationally ranked medical centers, UC San Francisco and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body to which the tumors have migrated. Known as prostate-specific membrane antigen PET imaging, or PSMA PET, the technique uses positron emission tomography in conjunction with a PET-sensitive drug that is highly effective in detecting prostate cancer throughout the body so that it can be better and more selectively treated.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: December 02, 2020)

quotesPSMA PET-CT imaging is now clinically available at 2 institutions in the US. This is an important step forward as this highly sensitive imaging approach is likely to grow into becoming a major component of prostate cancer management, both for disease assessment and ultimately for treatment assignment. It will be important to continue to collect detailed data and learn how to use this powerful new tool to our best advantage and how to avoid the inevitable pitfalls. Much to be done in this area. quotes

Add Comment 1 Comment
forumImage

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

(FDA.gov) May 20, 2020 - On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Today, the FDA also approved FoundationOne CDx (Foundation Medicine, Inc.) for selection of patients with mCRPC carrying HRR gene alterations and BRACAnalysis CDx test (Myriad Genetic Laboratories, Inc.) for selection of patients with mCRPC carrying germline BRCA1/2 alterations as companion diagnostic devices for treatment with olaparib.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: May 21, 2020)

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. With about 20% of patients potentially benefiting, the era of precision oncology is upon us. quotes

Add Comment 1 Comment
forumImage

ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

(Janssen) May 13, 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: May 14, 2020)

quotesWe expect to see overall survival results from several agents in non-metastatic castration resistant prostate cancer. I will be discussing these presentations at the ASCO meeting in a presentation entitled "Advanced Prostate Cancer: Putting Survival Into Perspective". I look forward to offering my commentary at the meeting. quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...